Possible heart failure caused by osimertinib in a lung cancer patient.
Paula Ruiz-BrionesVicente Escudero-VilaplanaRoberto Collado-BorrellJuan Vicente-ValorRosa AlvarezCristina Villanueva-BuenoÁlvaro Narrillos-MorazaAna HerranzMaria SanjurjoPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
There is scarce evidence in the literature concerning HF and important LVEF decrease due to osimertinib. However, its severity and repercussion for the patient justify the thorough screening of cardiovascular risk factors before starting the therapy.
Keyphrases
- cardiovascular risk factors
- heart failure
- small cell lung cancer
- case report
- advanced non small cell lung cancer
- epidermal growth factor receptor
- systematic review
- cardiovascular disease
- acute heart failure
- left ventricular
- atrial fibrillation
- stem cells
- bone marrow
- mesenchymal stem cells
- tyrosine kinase
- cardiac resynchronization therapy